Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOFDRA vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SOFDRA (sodium oxybate) is a CNS depressant that acts primarily via GABA-B receptors and also via a specific receptor for gamma-hydroxybutyrate (GHB). It is hypothesized to normalize nocturnal sleep architecture and improve daytime sleepiness in narcolepsy.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Treatment of cataplexy in patients with narcolepsy,Treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
1 drop (0.3 mg) in each eye once daily in the evening. Ophthalmic solution.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Terminal elimination half-life is 6-9 hours in healthy adults; may be prolonged up to 12-15 hours in patients with hepatic impairment.
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Sodium oxybate is primarily metabolized by the enzyme GHB dehydrogenase (a form of aldehyde dehydrogenase) and to a minor extent via CYP450 (not a major pathway). Metabolism is saturable and follows first-order kinetics at therapeutic doses.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <1% excreted unchanged in urine; biliary/fecal elimination accounts for approximately 20% of total clearance.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Approximately 95% bound to albumin and alpha-1-acid glycoprotein.
92-98% bound to plasma proteins (primarily albumin)
Volume of distribution is 0.8-1.2 L/kg, indicating extensive extravascular distribution.
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Oral bioavailability is approximately 75% due to first-pass metabolism; intravenous bioavailability is 100%.
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
No dosage adjustment required for renal impairment.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
No dosage adjustment required for hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Safety and efficacy in pediatric patients have not been established.
Not recommended for use in pediatric patients; safety and efficacy not established.
No dosage adjustment required; systemic exposure is similar to that in younger adults.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and RISK OF ABUSE. SOFDRA is a CNS depressant and can cause respiratory depression, hypotension, profound sedation, coma, and death. Concomitant use of alcohol or other CNS depressants increases these risks. SOFDRA is a Schedule III controlled substance with potential for abuse and dependence.
No FDA black box warning.
Central nervous system depression and respiratory depression,Risk of abuse and dependence (Schedule III controlled substance),Sodium content (high sodium intake may be problematic in patients with hypertension, heart failure, or renal impairment),Suicidal ideation and depression (monitor for psychiatric symptoms),Parasomnias (sleepwalking, confusional arousals),Requires strict adherence to dosing schedule (twice nightly, taken at bed and 2.5-4 hours later)
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Concomitant use of alcohol or other CNS depressants (e.g., benzodiazepines, opioids),Succinic semialdehyde dehydrogenase deficiency,Severe hepatic impairment (Child-Pugh C),History of substance abuse (relative contraindication)
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
No significant food interactions; take with or without food. Avoid grapefruit juice? Not clinically significant for SOFDRA.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
Sofdra (sofpironium bromide) is an anticholinergic agent. In animal reproduction studies, no structural abnormalities were observed at doses up to 3 times the maximum recommended human dose; however, anticholinergic drugs may cause fetal tachycardia and reduced fetal heart rate variability. Use in pregnancy should be avoided unless clearly needed. First trimester: limited data; no known major malformations. Second and third trimesters: potential for fetal anticholinergic effects, including decreased fetal movement and heart rate variability.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
No data on presence in human milk, effects on breastfed infant, or milk production. Because of the potential for serious adverse reactions (e.g., anticholinergic effects, including constipation and urinary retention) in breastfeeding infants, breastfeeding is not recommended during treatment with sofdr A. M/P ratio unknown.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
No specific dose adjustments are recommended during pregnancy due to lack of pharmacokinetic data in pregnant women. However, consider potential altered absorption and clearance; use lowest effective dose if required. Monitor for increased anticholinergic adverse effects due to possible changes in metabolism.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
SOFDRA (sofosbuvir 400mg/velpatasvir 100mg) is a pangenotypic NS5B polymerase inhibitor/NS5A inhibitor combination for chronic hepatitis C. Avoid coadministration with strong P-gp inducers (e.g., rifampin, carbamazepine, St. John's wort) which reduce sofosbuvir levels. Monitor for bradycardia when used with amiodarone; consider alternative antiarrhythmic. Dose adjustment not required for mild-moderate renal impairment, but not recommended for severe renal impairment (e GFR <30 m L/min). Test for HBV coinfection prior to initiation; HBV reactivation can occur during and after treatment. Duration: 12 weeks for treatment-naïve or peginterferon/ribavirin-experienced without cirrhosis or with compensated cirrhosis; 24 weeks with ribavirin for decompensated cirrhosis (Child-Pugh B/C). Check sustained virologic response (SVR) at 12 weeks post-treatment.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
Take exactly as prescribed; do not skip doses or stop early without consulting your doctor.,If you have hepatitis B, treatment may reactivate the virus; your doctor will monitor you.,Report any signs of severe bradycardia (fainting, dizziness, chest pain) especially if you take amiodarone.,Avoid St. John's wort, rifampin, and carbamazepine during treatment.,Take with or without food; swallow tablet whole.,Complete full course to achieve cure; missed doses should be taken as soon as remembered unless near next dose.,Use effective contraception during and for 6 months after if partner is of childbearing potential; if used with ribavirin, both partners must use two forms of contraception.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOFDRA vs AFEDITAB CR, answered by our medical review team.
SOFDRA is a Stimulant Laxative that works by SOFDRA (sodium oxybate) is a CNS depressant that acts primarily via GABA-B receptors and also via a specific receptor for gamma-hydroxybutyrate (GHB). It is hypothesized to normalize nocturnal sleep architecture and improve daytime sleepiness in narcolepsy.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOFDRA and AFEDITAB CR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOFDRA is: 1 drop (0.3 mg) in each eye once daily in the evening. Ophthalmic solution.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOFDRA and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOFDRA is classified as Category C. Sofdra (sofpironium bromide) is an anticholinergic agent. In animal reproduction studies, no structural abnormalities were observed at doses up to 3 times the maximum recommended h. AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.